Odyssey Therapeutics

Q2 FY2026 EarningsQ2 FY26 missed consensus across key profitability and cash flow metrics despite having zero revenue in line with expectations. Net loss (GAAP) of -$52.8M was significantly wider than the -$41.2M consensus, while GAAP EPS of -$1.74 missed the -$0.99 mean estimate by 75.72%. Cash used in operations for the first half of FY26 totaled -$75.5M, tracking worse than the annualized consensus expectation, primarily driven by R&D scaling for OD-001 and a non-cash $8.7M contingent consideration charge following the May 2026 IPO.